On July 8, ResMed declined 5.29% in regular trading, trading at approximately $208.45/share, with turnover of $47.03 million. The drop erased the prior session's 5.01% gain driven by the Noctrix Health acquisition.

On the news front, the company announced an agreement to sell its MatrixCare business to sharpen its focus on high-growth sleep and connected care markets. Simultaneously, RBC Capital significantly cut its price target from $321 to $276 while maintaining an Outperform rating. The consensus mean price target now stands at $272.16 according to FactSet-polled analysts.

The divestiture removes ResMed's out-of-hospital software segment serving senior living, skilled nursing, and hospice organizations. While the strategic pivot reinforces the company's core sleep franchise, the price target reduction follows a broader trend of analyst downgrades, including Morgan Stanley's earlier downgrade to Equal Weight with a $230 target citing GLP-1 drug competition and new market entrants, as well as KeyBanc and Citigroup trimming targets. The company is scheduled to report Q4 fiscal earnings on August 6, with consensus EPS expectations at $2.90.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)